Early induction of insulin sensitisation treated by tirzepatide: a prospective, single-arm, open-label study in Japanese individuals with obesity and type 2 diabetes.

Yamaguchi Y, Kuwata H, Imura M, Moyama S, Usui R, Matsushiro M, Hamamoto Y, Yamada Y, Seino Y, Yamazaki Y

Diabetologia22 Jul 2025

PMID40694059DOI10.1007/s00125-025-06493-5PepBankPUB-40694059

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanNon-randomized trialEfficacy outcome
In Japanese adults with obesity and type 2 diabetes, the glucose infusion rate rose from baseline after 12 weeks of tirzepatide, which shows better insulin sensitivity.
In plain wordsIn a small single-arm study in adults with obesity and type 2 diabetes, insulin sensitivity rose during 12 weeks of tirzepatide.
Peptide
Tirzepatide
Outcome
IncreaseGlucose infusion rate (insulin sensitivity)
Study
n = 16
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
2.5 mg once weekly for 4 weeks, then 5 mg for 8 weeks · 12 weeksAs given in this study (human).
Measurements
Glucose infusion rate
3.21 mg/min/kg
baseline
Glucose infusion rate
5.16 mg/min/kg
after treatment
Source sentences
Summary
The GIR increased from 3.21 to 5.16 mg min^-1 kg^-1 (p<0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
This prospective, single-arm, open-label, single-centre study was conducted in obese individuals with type 2 diabetes.
Summary · context
Participants received tirzepatide 2.5 mg once weekly for 4 weeks; the dose was then increased to 5 mg for the remaining 8 weeks.
Report a problemFND-4069405901
02HumanNon-randomized trialEfficacy outcome
In Japanese adults with obesity and type 2 diabetes, HbA1c fell from 63.4 to 43.6 mmol/mol over 12 weeks of tirzepatide.
In plain wordsIn a small single-arm study, long-term blood sugar (HbA1c) fell during 12 weeks of tirzepatide.
Peptide
Tirzepatide
Outcome
DecreaseHbA1c change
Study
n = 16
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
2.5 mg once weekly for 4 weeks, then 5 mg for 8 weeks · 12 weeksAs given in this study (human).
Measurements
HbA1c
63.4 mmol/mol
baseline
HbA1c
43.6 mmol/mol
after treatment
Source sentences
Summary
HbA_1c decreased from 63.4 to 43.6 mmol/mol (7.95% to 6.14%, p<0.001)
2 context sentences(design, population, supporting numbers)
Summary · context
This prospective, single-arm, open-label, single-centre study was conducted in obese individuals with type 2 diabetes.
Summary · context
Participants received tirzepatide 2.5 mg once weekly for 4 weeks; the dose was then increased to 5 mg for the remaining 8 weeks.
Report a problemFND-4069405902
03HumanNon-randomized trialEfficacy outcome
In Japanese adults with obesity and type 2 diabetes, body weight fell by 4.9 kg (5.0%) over 12 weeks of tirzepatide.
In plain wordsIn a small single-arm study, body weight fell by about 5% during 12 weeks of tirzepatide.
Peptide
Tirzepatide
Outcome
DecreaseBody weight change
Study
n = 16
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
2.5 mg once weekly for 4 weeks, then 5 mg for 8 weeks · 12 weeksAs given in this study (human).
Measurements
Body weight decrease
4.9 kg
after treatment
Body weight decrease
5%
after treatment
Source sentences
Summary
body weight decreased by 4.9 kg (5.0%, p<0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
This prospective, single-arm, open-label, single-centre study was conducted in obese individuals with type 2 diabetes.
Summary · context
Participants received tirzepatide 2.5 mg once weekly for 4 weeks; the dose was then increased to 5 mg for the remaining 8 weeks.
Report a problemFND-4069405903
04HumanNon-randomized trialEfficacy outcome
In Japanese adults with obesity and type 2 diabetes, muscle mass fell significantly (by 1.8%) over 12 weeks of tirzepatide.
In plain wordsIn a small single-arm study, muscle mass fell slightly during 12 weeks of tirzepatide.
Peptide
Tirzepatide
Outcome
DecreaseMuscle mass change
Study
n = 16
Analysis
Secondary
Outcome group
Body composition · Metabolic and weight
Studied dose
2.5 mg once weekly for 4 weeks, then 5 mg for 8 weeks · 12 weeksAs given in this study (human).
Measurements
Muscle mass decrease
1.8%
after treatment
Source sentences
Summary
Muscle mass, fat mass and fat percentage significantly decreased by 1.8%, 9.1% and 4.5%, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
This prospective, single-arm, open-label, single-centre study was conducted in obese individuals with type 2 diabetes.
Summary · context
Participants received tirzepatide 2.5 mg once weekly for 4 weeks; the dose was then increased to 5 mg for the remaining 8 weeks.
Report a problemFND-4069405904
05HumanNon-randomized trialEfficacy outcome
In Japanese adults with obesity and type 2 diabetes, fat mass fell significantly (by 9.1%) over 12 weeks of tirzepatide.
In plain wordsIn a small single-arm study, body fat mass fell during 12 weeks of tirzepatide.
Peptide
Tirzepatide
Outcome
DecreaseFat mass change
Study
n = 16
Analysis
Secondary
Outcome group
Body composition · Metabolic and weight
Studied dose
2.5 mg once weekly for 4 weeks, then 5 mg for 8 weeks · 12 weeksAs given in this study (human).
Measurements
Fat mass decrease
9.1%
after treatment
Source sentences
Summary
Muscle mass, fat mass and fat percentage significantly decreased by 1.8%, 9.1% and 4.5%, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
This prospective, single-arm, open-label, single-centre study was conducted in obese individuals with type 2 diabetes.
Summary · context
Participants received tirzepatide 2.5 mg once weekly for 4 weeks; the dose was then increased to 5 mg for the remaining 8 weeks.
Report a problemFND-4069405905
06HumanNon-randomized trialEfficacy outcome
In Japanese adults with obesity and type 2 diabetes, fat percentage fell significantly (by 4.5%) over 12 weeks of tirzepatide.
In plain wordsIn a small single-arm study, the share of body fat fell during 12 weeks of tirzepatide.
Peptide
Tirzepatide
Outcome
DecreaseFat percentage change
Study
n = 16
Analysis
Secondary
Outcome group
Body composition · Metabolic and weight
Studied dose
2.5 mg once weekly for 4 weeks, then 5 mg for 8 weeks · 12 weeksAs given in this study (human).
Measurements
Fat percentage decrease
4.5%
after treatment
Source sentences
Summary
Muscle mass, fat mass and fat percentage significantly decreased by 1.8%, 9.1% and 4.5%, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
This prospective, single-arm, open-label, single-centre study was conducted in obese individuals with type 2 diabetes.
Summary · context
Participants received tirzepatide 2.5 mg once weekly for 4 weeks; the dose was then increased to 5 mg for the remaining 8 weeks.
Report a problemFND-4069405906
07HumanNon-randomized trialEfficacy outcome
In Japanese adults with obesity and type 2 diabetes, glucagon fell from 28.8 to 20.8 pg/ml over 12 weeks of tirzepatide.
In plain wordsIn a small single-arm study, blood glucagon fell during 12 weeks of tirzepatide.
Peptide
Tirzepatide
Outcome
DecreaseGlucagon level
Study
n = 16
Analysis
Secondary
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
2.5 mg once weekly for 4 weeks, then 5 mg for 8 weeks · 12 weeksAs given in this study (human).
Measurements
Glucagon
28.8 pg/ml
baseline
Glucagon
20.8 pg/ml
after treatment
Source sentences
Summary
Glucagon decreased significantly from 28.8 pg/ml to 20.8 pg/ml.
2 context sentences(design, population, supporting numbers)
Summary · context
This prospective, single-arm, open-label, single-centre study was conducted in obese individuals with type 2 diabetes.
Summary · context
Participants received tirzepatide 2.5 mg once weekly for 4 weeks; the dose was then increased to 5 mg for the remaining 8 weeks.
Report a problemFND-4069405907
08HumanNon-randomized trialEfficacy outcome
In Japanese adults with obesity and type 2 diabetes on tirzepatide, simple linear regression showed no significant relationship between changes in GIR and other clinical variables.
In plain wordsIn a small single-arm study, the rise in insulin sensitivity was not clearly linked to changes in the other measures.
Peptide
Tirzepatide
Outcome
No significant changeAssociation of GIR change with other clinical variables
Study
n = 16
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
2.5 mg once weekly for 4 weeks, then 5 mg for 8 weeks · 12 weeksAs given in this study (human).
Source sentences
Summary
However, simple linear regression analysis revealed no significant relationship between changes in GIR and other clinical variables.
2 context sentences(design, population, supporting numbers)
Summary · context
This prospective, single-arm, open-label, single-centre study was conducted in obese individuals with type 2 diabetes.
Summary · context
Participants received tirzepatide 2.5 mg once weekly for 4 weeks; the dose was then increased to 5 mg for the remaining 8 weeks.
Report a problemFND-4069405908

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 03:07 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Early induction of insulin sensitisation treated by tirzepatide: a prospective, single-arm, open-label study in Japanese individuals with obesity and type 2 diabetes.

Summary

Results from this study8

Version history

Subjects

Publication types

MeSH terms

Keywords